ID   LNCaP-AR
AC   CVCL_C7XA
DR   Wikidata; Q123032971
RX   PubMed=14702632;
RX   PubMed=35502546;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line).
CC   Transfected with: HGNC; 644; AR.
CC   Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC   Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1379 ! LNCaP clone FGC
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 29-06-23; Last updated: 30-01-24; Version: 2
//
RX   PubMed=14702632; DOI=10.1038/nm972;
RA   Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R.L.,
RA   Rosenfeld M.G., Sawyers C.L.;
RT   "Molecular determinants of resistance to antiandrogen therapy.";
RL   Nat. Med. 10:33-39(2004).
//
RX   PubMed=35502546; DOI=10.1158/0008-5472.CAN-22-1065;
RA   Abate-Shen C., Nunes de Almeida F.;
RT   "Establishment of the LNCaP cell line -- the dawn of an era for
RT   prostate cancer research.";
RL   Cancer Res. 82:1689-1691(2022).
//